Targeting MDM2-p53 in cancer: The story of brigimadlin
Learn about the discovery of Brigimadlin, our MDM2-p53 antagonist, that is being developed for the treatment of dedifferentiated liposarcoma, a rare cancer
Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
Did you know that Boehringer is still family-owned? Read this article to learn more about our culture. Check out our Careers Page for more talent insights!
The Speak Up portal provides a safe environment to report potential violations and is open to any person worldwide. We take any reports of potential violations seriously.
It’s the smart combination of our cancer cell-directed and immuno-oncology approaches that may offer the greatest benefit for people living with cancer.
A career at the intersection of science and marketing
A member of the Animal Health digital marketing team, our colleague Missy talks about her purpose to bring transformative technologies to the vet community
Our employees are the foundation of our innovative strength. We continue to put people first in everything we do and support our employees in the key moments of their careers.